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ABSTRACT
Background. Diabetes mellitus (DM) is a common and 
debilitating chronic disease with increasing prevalence 
in the world and in Iran. Helicobacter pylori (H. pylori) 
is a gram-negative bacillus that causes gastritis and 
peptic ulcer disease and stomach cancer. It is more 
common in developing countries. Several studies have 
shown the possible association between H. pylori in-
fection and DM. We performed this study to evaluate 
H. pylori infection in type 2 diabetes mellitus (T2DM) 
patients in comparison to non-diabetic individuals.
Methods. In a case-control study 99 T2DM patients 
(aged 31 to 96 years) who referred to Urmia Imam 
Khomaini hospital and 96 non-diabetic controls were 
included. Venous blood samples were received from 
all participants and fasting blood glucose (FBG), HbA1c 
and serum H. pylori IgG levels were measured. For all 
individuals demographic data, including age, sex and 
body mass index (BMI) were recorded. H. pylori IgG 
levels greater than 10 U/ml was considered as H. pylori 
infection. H. pylori IgG serum levels of all of T2DM 
patients and control group were compared with each 
other. Data were analyzed using SPSS version 17. We 
used independent T-test, Chi-square and Fisher exact 
test for statistical analysis. The level of significance 
was considered as p-value < 0.05. 
Results. Means age of T2DM patients and control 
group were 59.77 ± 13.25 and 63.43 ± 13.16 years 
respectively and there was not significant difference 
between two groups (p = 0.05). Frequency of positive 
H. pylori serology in T2DM patients was 69.7% and 
in non-diabetic group was 66.7% and there was not 
significant difference between two groups in this re-
gard (p = 0.65). Mean ± SE serum H. pylori IgG levels 
in T2DM and non-diabetic subjects was 45.78 ± 4.82 
and 44.35 ± 4.83 U/ml respectively (p = 0.83). Mean 
HbA1c level was significantly higher in T2DM patients 
compared to control group (8.40 ± 2.02 and 5.29 ± 
0.45 respectively, p < 0.001).
Conclusions. According to the results of this study 
frequency of H. pylori infection and also serum H. 
pylori IgG levels in diabetic patients does not differ 
from non-diabetics subjects. (Clin Diabetol 2020; 9)
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Introduction
Diabetes is a common and debilitating chronic 
disease with increasing prevalence both in the world 
and in Iran [1–3]. Helicobacter pylori (H. pylori) is a 
gram-negative bacillus that causes gastritis and peptic 
ulcer disease and stomach cancer [4]. It is more com-
mon in developing countries [5]. Some studies have 
shown that H. pylori infection has been associated 
with non-gastrointestinal diseases such as ischemic 
heart disease, neurologic diseases, and autoimmune 
thyroid disorders [5–10]. Several studies have shown 
the association between H. pylori infection and diabe-
tes mellitus [5, 11, 12]. The issue of whether H. pylori 
infection causes diabetes or those with diabetes are 
more likely to develop H. pylori infection is still not 
fully understood [12]. One of the proposed mecha-
nisms of developing diabetes in patients with H. pylori 
infection can be increased insulin resistance [5]. Other 
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mechanisms include chronic inflammation, reduced 
insulin secretion, and increased synthesis of some of 
the diabetogenic hormones such as leptin that leads 
to insulin resistance [5]. Furthermore decreased ghrelin 
level in patients with H. pylori infection leads to reduced 
energy consumption and weight gain [5].
In some studies, there is even a significant correla-
tion between microvascular complications of diabetes 
and helicobacter infection such as microalbuminuria 
and neuropathy [13, 14]. In contrast, in some studies, 
there was no association between H. pylori infection 
and diabetes mellitus found [15].
Given the controversy and limited studies in this 
field in Iran, we designed this study to investigate the 
association of H. pylori infection with type 2 diabetes.
Materials and methods
In this case-control study 99 type 2 diabetes mel-
litus (T2DM) patients over the age of thirty (aged 31–96 
years) who referred to Endocrinology department of 
Urmia Imam Khomaini hospital and 96 non-diabetic 
controls were included. Subjects who had autoimmune, 
infectious or rheumatologic diseases and those taking 
proton pomp inhibitors within one month before the 
study as well as patients treated with immunosuppres-
sive drugs were excluded from study.
The subjects in our study had no predominant 
symptoms of upper gastrointestinal tract involvement 
and they had not been treated with anti-helicobacter 
drugs for a month before study initiation. The control 
group was selected from non-diabetic healthy individu-
als who referred to the ophthalmology department 
of Imam Khomaini hospital and did not present any 
exclusion criteria.
The study began after approval of Urmia University 
of medical sciences ethic committee and after obtain-
ing written consent from all individuals. Venous blood 
samples were received from participants in the fasting 
state for fasting blood glucose (FBG), HbA1c and serum 
H. pylori IgG levels. FBG and HbA1c were measured 
by enzymatic method (Pars Azmun kite, Tehran, Iran) 
and turbidimetric immunoassay (Aptec kite, Belgium) 
respectively and serum H. pylori IgG level was measured 
by ELISA method (Pishtazteb kite, Tehran, Iran). For all 
subjects demographic data, including age, sex weight, 
height and body mass index (BMI) were recorded. 
H. pylori IgG levels greater than 10 U/ml was considered 
as H. pylori infection. H. pylori IgG serum levels of all 
of T2DM patients and control group were compared 
with each other. Data were analyzed by independent 
T-test, Chi-square and Fisher exact tests using SPSS 
version 17. The level of significance was considered as 
p-value < 0.05.
Results
Demographic characteristics and laboratory test 
results of two study groups are demonstrated in Table 1.
As shown in Table 1, there is no statistically signifi-
cant difference between the two groups in terms of age 
(p = 0.05). Also, the percentage of female population 
in the two groups was not statistically significant.
Both FBG and HbA1c mean values were significantly 
higher in T2DM patients than in control group (Table 1). 
Frequency of positive H. pylori serology in T2DM patients 
was 69.7% (n = 69) and in non-diabetic group was 
66.7% (n = 64) and there was not significant difference 
between these two groups in this regard (p = 0.65). 
Mean ± SE (standard error) serum H. pylori IgG levels 
in T2DM and non-diabetic subjects were 45.78 ± 4.82 
and 44.35 ± 4.83 U/ml respectively and the difference 
between these two groups was not statistically signifi-
cant (p = 0.83). 
FBG, HbA1c and BMI mean values did not differ sig-
nificantly between diabetic patients with and without 
H. pylori infection (Table 2). Also as shown in Table 3 
the difference between FBG, HbA1c and BMI mean 
values was not statistically significant between control 
subjects with H. pylori infection and without it.
Table 1. Demographic characteristics and laboratory test results of type 2 diabetes mellitus (T2DM) patients and control 
group
Parameter T2DM patients (n = 99) Control group (n = 96) p value
Age (years) 59.77 ± 13.25 63.43 ± 13.16 0.05
Female (%) 53(53.5%) 49(51% ) 0.72
Weight [kg] 73.56 ± 14.44 066.54 ± 14.34 0.001
Height [cm] 163.99 ± 9.8100 161.02 ± 10.46 0.04
BMI ([kg/m2] 27.45 ± 5.280 25.61 ± 4.47 0.009
HbA1c (%) 8.40 ± 2.02 05.29 ± 0.45 < 0.001
FBG [mg/dL] 201.69 ± 78.710 090.39 ± 24.25 0.001
Data are expressed as mean ± SD. FBG — fasting blood glucose; BMI — body mass index
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Moreover in the total population of our study, 
the mean value of BMI was 26.68 ± 4.85 kg/m2 in 
Helicobacter infected subjects and 26.25 ± 5.25 kg/m2 
in non-infected individuals, and there was no statisti-
cally significant difference between these two groups 
(p = 0.57).
Discussion
Type 2 diabetes mellitus is a common systemic 
disease with serious complications [1, 2, 16]. In recent 
years, several studies have examined the association 
between T2DM and H. pylori infection and some of 
them have confirmed this association but others have 
not shown any relationship between these two. In the 
present study, the percentage of T2DM patients with 
H. pylori infection was 69.7% and in the control group 
it was 66.7% and the difference between these two 
groups was not statistically significant. Similar to our 
study in a cross-sectional study conducted by Jafar-
zadeh et al. on 100 T2DM patients and 100 healthy 
controls in 2011 in Rafsanjan city of Iran, there was 
no significant difference between the prevalence of 
positive Helicobacter antibodies (IgG) levels among 
patients with type 2 diabetes and healthy subjects 
(76% vs. 75% respectively). But in their study healthy 
individuals compared with diabetic patients, had 
significantly higher levels of anti-Helicobacter IgG 
antibodies (131.63 ± 11.68 vs. 54.43 ± 4.50 U/ml ; 
p < 0.0001) [17]. Our results are consistent with 
study by Jafarzadeh et al. regarding the similar rate of 
H. pylori seropositivity in the two study groups and lack 
of association between T2DM and H. pylori infection 
[17]. However, in our study, the mean serum level of 
anti-Helicobacter IgG antibiodies in diabetic patients 
was higher than in the control group (45.78 ± 4.82 
and 44.35 ± 4.83 respectively), but this difference was 
not statistically significant (p = 0.83).
In a study by Bener and colleagues on 210 pa-
tients with type 2 diabetes and the same number of 
non-diabetic patients, a higher percentage of diabetic 
patients than non-diabetic ones had positive H. pylori 
antibody (IgG) levels (76.7% vs. 64.8% respectively, 
p = 0.01) which is against our study results [18].
In the research conducted by Devrajani et al. on 74 
diabetes cases and 74 non-diabetic controls in Pakistan, 
the percentage of positive Helicobacter pylori stool 
antigen was 73% and 51.4%, respectively and the dif-
ference between these two groups in this regard was 
statistically significant (p = 0.0001). They suggested 
that patients with diabetes are susceptible to H. pylori 
infection, therefore they recommended screening for 
H. pylori infection in diabetic patients [19].
Furthermore Bajaj et al. in the study on 80 diabetic 
patients and 80 controls, showed that the prevalence 
of H. pylori infection in diabetic patients is consider-
ably higher than in the control group (77.5 vs. 58.3% 
respectively, p = 0.02). Also, in their study the average 
HbA1c levels in the diabetic group with H. pylori was 
significantly higher than those without Helicobacter 
infection [20]. 
Therefore, they suggested that H. pylori infection is 
associated with higher HbA1c levels and inappropriate 
blood glucose control, but our study results are not 
consistent with the results of the study by Bajaj et al.
In a study by Zojaji et al. on 85 T2DM patients in 
Iran, the mean serum HbA1c level 3 months after treat-
ment of H. pylori infection was significantly reduced 
compared to its pre-treatment level, however, fast-
ing blood glucose did not change significantly after 
treatment compared to the pretreatment state. They 
Table 2. Glycemic parameters and BMI in diabetic patients with and without H. pylori infection
DM H. pylori+ DM H. pylori– p-value
FBG [mg/dL] 191.66 ± 64.33 224.7 ± 102.18 0.05
HbA1c (%) 8.33 ± 1.95 8.55 ± 2.22 0.63
BMI [kg/m2] 27.47 ± 5.220 27.40 ± 5.490 0.96
DM — diabetes mellitus; FBG — fasting blood glucose; BMI — body mass index
Table 3. Glycemic parameters and BMI in control group with and without H. pylori infection
Control H. pylori+ Control H. pylori– p-value
FBG [mg/dL] 92.73 ± 27.86 85.71 ± 13.8 0.1
HbA1c (%) 5.34 ± 0.48 5.19 ± 0.37 0.13
BMI [kg/m2] 25.83 ± 4.300 25.16 ± 4.850 0.49
FBG — fasting blood glucose; BMI — body mass index
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concluded that H. pylori eradication has beneficial ef-
fects on the glycemic control in diabetic patients [21]. 
However, Wada and colleagues, in a retrospective study 
in Japan, showed that treatment of Helicobacter pylori 
infection in T2DM patients does not improve HbA1c 
levels [22].
Also Vafaeimanesh et al. in the study on T2DM pa-
tients who were treated with oral medications showed 
that H. pylori infection therapy has no beneficial effects 
on blood glucose profiles, in addition they had lower 
rates of successful response to anti H. pylori regimen 
compared with non-diabetic subjects [23].
The study of Quatrini et al. in Italy, also supports 
the higher percentage of H. pylori infection in diabetic 
patients population (insulin dependent and non-insulin 
dependent) compared with non-diabetic subjects (69% 
and 46% respectively, p = 0.007) [24]. Although the 
different outcomes of their study comparing to our 
study may be due to the fact that they used respiratory 
urease test for the detection of H. pylori infection, while 
we have used ELISA method (anti H. pylori IgG levels).
Our study shows that there is no significant 
relationship between H. pylori infection and type 2 
diabetes.
H. pylori infection diagnostic tests are classified 
into two categories of invasive and non-invasive tools 
and various previous studies have used either one 
method alone or a combination of several methods 
[25, 26].
Although urea breath test is more accurate and 
commonly used as a standard diagnostic test [25, 26], 
we did not use it because of its high cost and unavail-
ability in our center.
Among the different methods for H. pylori infec-
tion detection, we used serology (ELISA) becauseof its 
convenience and availability and its low cost in this 
study. Although serologic results also usually not in-
fluenced by antibiotic or PPI (proton pump inhibitors) 
treatment [26], we did not include subjects that were 
taking PPI or anti-helicobacter medications within one 
month before the study. 
One of the limitations of our study is the use of 
only one method (ELISA) for the diagnosis of H. pylori 
infection. As mentioned earlier given the high cost of 
respiratory urease test and its unavailability as well 
as the financial limitations we could not use neither 
this test nor any additional method such as H. pylori 
fecal antigen test to confirm the diagnosis of H. pylori 
infection.
Another limitation of our study was the lack of 
assessment of the upper gastrointestinal symptoms 
in diabetic patients and not considering it as the in-
clusion criteria, although most of participants were 
asymptomatic and did not report any significant upper 
gastrointestinal symptoms.
Factors such as race, geographic region, economic 
state, different dietary and drug regimens used to 
control blood glucose, as well as different diagnostic 
methods used to detect H. pylori infection, can influ-
ence the results of different studies.
More prospective studies with long-term follow-
up of H. pylori infected patients in terms of the risk of 
type 2 diabetes development are needed. These studies 
should use more accurate methods or a combination 
of several diagnostic tools for H. pylori infection what 
can be helpful in revealing the relationship between 
H. pylori infection and diabetes. As well as future 
research on the role of oral hypoglycemic drugs may 
be useful in the development of H. pylori infection in 
diabetic type 2 patients.
Conclusion
Based on the results of this study, it seems that 
there is no relationship between H. pylori infection 
and type 2 diabetes.
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